Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a …
Importance Glioblastoma is the most lethal primary brain cancer. Clinical outcomes for
glioblastoma remain poor, and new treatments are needed. Objective To investigate
whether adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) to
standard of care (SOC) extends survival among patients with glioblastoma. Design, Setting,
and Participants This phase 3, prospective, externally controlled nonrandomized trial
compared overall survival (OS) in patients with newly diagnosed glioblastoma (nGBM) and …
glioblastoma remain poor, and new treatments are needed. Objective To investigate
whether adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) to
standard of care (SOC) extends survival among patients with glioblastoma. Design, Setting,
and Participants This phase 3, prospective, externally controlled nonrandomized trial
compared overall survival (OS) in patients with newly diagnosed glioblastoma (nGBM) and …
